Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections.
We report a case of simultaneous infection with hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) in a 26-year-old Japanese homosexual man. He was admitted to our hospital for acute hepatitis caused by HBV. At that time, HIV-1antibody (Ab) was not detected in his serum. After 6 months, he was readmitted to our hospital for further examination of his liver because of confined liver enzyme abnormalities. Anti-HIV- Ab was detected in his serum by both enzyme immunosorbent assay (EIA) and particle agglutination (PA). His serum HIV-1 RNA level was 50 x 10(4) copies/ml and serum levels of HBV DNA polymerase (DNA-P) and HBV DNA were 6535cpm and 3 plus (>1000 copies/ml). His clinical course and laboratory data suggested progression from acute to chronic hepatitis related to coinfection with HIV-1. The diagnosis was chronic active hepatitis caused by HBV as an opportunistic infection due to coinfection with HIV-1. We began highly active antiretroviral therapy (HAART) because interferon (IFN) therapy was ineffective. HAART was started at an initial dosage of 600 mg zidovudine (AZT), 300 mg lamivudine (3TC), and 2400 mg indinavir (IDV) daily. After 4 weeks, the serum level of HBV DNA-polymerase (p) had decreased markedly to 37cpm and that of HIV-1 RNA had decreased to below the sensitivity threshold, indicating considerable suppression of the replication of these viruses by the treatment. But HBV DNA remained at low levels. Although the incidence of HBV infection in patients with HIV-1 infection has been reported to be high in the United States and Europe, simultaneous HBV and HIV-1 infection leading to persistent HBV infection is rare.
Nagai
K
K
Department of Internal Medicine, Saiseikai Yokohama-shi Nanbu Hospital, Yokohama, Japan.
Hosaka
H
H
Kubo
S
S
Nakamura
N
N
Shinohara
M
M
Nonaka
H
H
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D001707:Biopsy, Needle; D004359:Drug Therapy, Combination; D015684:Gene Products, pol / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification; D006510:Hepatitis B Antibodies / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage; D019259:Lamivudine / Q000008:administration & dosage; D008099:Liver / Q000473:pathology; D008297:Male; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D015684:Gene Products, pol; D006510:Hepatitis B Antibodies; C066027:P protein, Hepatitis B virus; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir